October 5, 2026 Epicrispr Reports Positive Six-Month Data at The World Muscle Society Meeting Demonstrating Increased Lean Muscle Volume and Muscle Strength in FSHD Patients Treated with EPI-321
August 11, 2026 Epicrispr Biotechnologies Closes $90 Million Oversubscribed Series C Financing to Advance First-in-Class Epigenetic Therapy Toward Pivotal Studies in FSHD
July 7, 2026 Epicrispr Completes Enrollment and Dose Escalation in First-in-Human EPI-321 Trial for FSHD
June 26, 2026 Epicrispr Reports First Clinical Evidence of Increased Lean Muscle Volume in Patients with FSHD Following Treatment with EPI-321
March 24, 2026 Epicrispr Biotechnologies Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2026
January 8, 2026 Epicrispr Reports Early Clinical Activity and Favorable Safety Profile in First-in-Human Epigenetic Editing Study for FSHD
December 8, 2025 Epicrispr Biotechnologies to Present at 44th Annual J.P. Morgan Healthcare Conference
August 5, 2025 Epicrispr Biotechnologies Doses First Patient in First-in-Human Clinical Trial of EPI-321 for Facioscapulohumeral Muscular Dystrophy
May 12, 2025 Epicrispr Biotechnologies Named Finalist in XPRIZE Healthspan Competition FSHD Bonus Prize
May 5, 2025 Epicrispr Biotechnologies Announces Five Presentations Highlighting Advances in Epigenetic Modulation and AAV Manufacturing at ASGCT 2025 Annual Meeting
April 23, 2025 Epicrispr Biotechnologies Partners with Springbok Analytics to Integrate AI Muscle Analysis in First-in-Human FSHD Study
April 3, 2025 Epicrispr Biotechnologies Announces FDA Clearance of IND Application for EPI-321, A First-in-Class Epigenetic Therapy for FSHD
